Lack of intent evidence dooms drugmaker fine
Ruling that Switzerland’s antitrust authority failed to provide sufficient evidence of anticompetitive intent, a Swiss court has found that Pfizer, Eli Lilly, and Bayer are no longer guilty of illegally setting minimum prices for their erectile dysfunction medication.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.